Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -54.45% is 97% above its 5-year average of -1748.56%, near the high end of its 5-year range (-8806.47%–58.74%).
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -3523.09%.
EBITDA MARGIN
-54.45%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
-4090.27%
EBITDA MARGIN AVG 5Y
-1748.56%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
+98.67%
CURRENT VS 5Y AVG
+96.89%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Denali Therapeutics Inc.
Market Cap
$3.16B
EBITDA Margin
-54.45%
TTM Avg
N/A
3Y Avg
-4090.27%
5Y Avg
-1748.56%
Market Cap
$3.15B
EBITDA Margin
-1.82%
TTM Avg
-32.91%
3Y Avg
-2154.05%
5Y Avg
-2154.05%
Market Cap
$3.09B
EBITDA Margin
-359.19%
TTM Avg
-174.35%
3Y Avg
-417.41%
5Y Avg
-1450.57%
Market Cap
$2.88B
EBITDA Margin
89.92%
TTM Avg
49.57%
3Y Avg
44.47%
5Y Avg
4968.54%
Market Cap
$3.44B
EBITDA Margin
10.88%
TTM Avg
18.32%
3Y Avg
-3.89%
5Y Avg
-19.05%
Market Cap
$2.87B
EBITDA Margin
22.42%
TTM Avg
17.70%
3Y Avg
-0.76%
5Y Avg
-37.34%
Market Cap
$3.58B
EBITDA Margin
-1.38%
TTM Avg
-8.27%
3Y Avg
-15.09%
5Y Avg
-16.30%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | $3.16B | -54.45% | N/A | -4090.27% | -1748.56% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.15B | -1.82% | -32.91% | -2154.05% | -2154.05% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.09B | -359.19% | -174.35% | -417.41% | -1450.57% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.25B | N/A | N/A | N/A | N/A |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | 89.92% | 49.57% | 44.47% | 4968.54% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.44B | 10.88% | 18.32% | -3.89% | -19.05% |
| TransMedics Group, Inc. (TMDX)vs › | $2.87B | 22.42% | 17.70% | -0.76% | -37.34% |
| AtriCure, Inc. (ATRC)vs › | $2.87B | 3.20% | -0.69% | -3.43% | -1.09% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.58B | -1.38% | -8.27% | -15.09% | -16.30% |
| Celcuity Inc. (CELC)vs › | $3.59B | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
-54.5%
Operating Margin
0.0%
Net Margin
-14191.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -3523.09% |
| 2023-09-30 | -8806.47% |
| 2023-06-30 | 58.74% |
| 2023-03-31 | -315.21% |
| 2022-12-31 | -984.66% |
| 2022-09-30 | -2959.96% |
| 2022-06-30 | -113.08% |
| 2022-03-31 | -152.87% |
| 2021-12-31 | -599.54% |
| 2021-09-30 | -1578.16% |
| 2021-06-30 | -259.88% |
| 2021-03-31 | -872.30% |
| 2020-12-31 | 77.71% |
| 2020-09-30 | -617.06% |
| 2020-06-30 | -1011.32% |
| 2020-03-31 | -1605.38% |
| 2019-12-31 | -1192.27% |
| 2019-09-30 | -354.79% |
| 2019-06-30 | -1456.28% |
| 2019-03-31 | -953.75% |
| 2018-12-31 | 61.35% |
| 2018-09-30 | -2982.18% |
| 2018-06-30 | -3369.36% |
| 2018-03-31 | -3883.62% |
